Mazdutide vs Survodutide

Mazdutide vs Survodutide: Overview

Mazdutide and survodutide are two investigational dual-receptor agonists that share a common pharmacological feature — both incorporate glucagon receptor agonism — but differ in their second receptor target. Mazdutide is a dual GLP-1 and glucagon receptor agonist developed primarily in Chinese clinical populations, while survodutide is a dual glucagon and GLP-1 receptor agonist that has been evaluated in global clinical programmes. The comparison of mazdutide vs survodutide is of particular interest because these compounds share the same two receptor targets but differ in their molecular design, receptor binding ratios, and clinical development strategies.

The investigation of survodutide vs mazdutide provides a unique opportunity to examine how two compounds targeting the same pair of receptors can differ in their clinical profiles. Both harness the energy expenditure-enhancing and hepatic fat-reducing properties of glucagon receptor agonism while leveraging GLP-1 receptor agonism for appetite suppression and glycaemic improvement. However, differences in molecular structure, receptor affinity ratios, and pharmacokinetic properties may translate into distinct efficacy and safety outcomes.

Both compounds are advancing through clinical development with promising trial data. This comparison examines the available evidence to help researchers understand the nuances between these two dual GLP-1/glucagon receptor agonists.

Mechanism of Action

Mazdutide is a dual GLP-1 and glucagon receptor agonist designed as a single peptide molecule that activates both receptor systems. The GLP-1 receptor component provides glucose-dependent insulinotropic activity, appetite suppression, and delayed gastric emptying. The glucagon receptor component promotes hepatic energy expenditure, fatty acid oxidation, and thermogenesis. Mazdutide has been engineered with a specific ratio of GLP-1 to glucagon receptor activity intended to maximise metabolic benefit while maintaining glycaemic safety (Ji et al., 2025).

Survodutide similarly functions as a dual glucagon and GLP-1 receptor agonist, engaging the same two receptor targets as mazdutide. The glucagon component is designed to enhance energy expenditure and reduce hepatic fat accumulation, while the GLP-1 component provides complementary appetite suppression and glucose-lowering effects. The specific receptor binding characteristics and agonist potency ratios of survodutide have been calibrated to achieve an optimal balance between the metabolic-enhancing effects of glucagon and the glucose-lowering properties of GLP-1 (le Roux et al., 2024).

Although both mazdutide vs survodutide target GLP-1 and glucagon receptors, the two compounds are structurally distinct molecules with potentially different receptor selectivity profiles, binding affinities, and signalling biases. These molecular differences may account for variations in their clinical efficacy and tolerability, even though they act through the same fundamental receptor pathways. Research into the relationship between glucagon receptor agonism and metabolic outcomes has provided mechanistic context for both agents (Elmendorf et al., 2026; Neff et al., 2025).

Clinical Evidence

Mazdutide has been evaluated in multiple clinical trials, with a particularly robust evidence base in Chinese populations. A phase 3 trial in Chinese adults with obesity or overweight demonstrated clinically significant weight reduction with once-weekly mazdutide (Ji et al., 2025). Additional phase 3 trials have compared mazdutide against placebo and active comparators in type 2 diabetes, including head-to-head studies against dulaglutide showing superior glycaemic outcomes (Guo et al., 2026; Zhu et al., 2026). The DREAMS-3 trial has been designed to compare mazdutide with semaglutide in type 2 diabetes (Luo et al., 2026). A phase 1 high-dose study has also explored the upper dose range for potential weight management applications (Bhattachar et al., 2025).

Survodutide’s clinical evidence includes a phase 2 dose-finding trial in adults with overweight or obesity, which demonstrated dose-dependent weight reductions of up to approximately 14.9% over 46 weeks (le Roux et al., 2024). The compound has also shown efficacy in hepatic fat reduction. The SYNCHRONIZE phase 3 programme is currently evaluating survodutide across multiple indications, with baseline characteristics published for the cardiovascular outcomes trial and weight management trials (Platz et al., 2025; Wharton et al., 2026; le Roux et al., 2026).

A systematic review and meta-analysis has specifically evaluated survodutide’s efficacy on glycaemic control and weight loss, providing a pooled assessment of available trial data (Xiao et al., 2025). Network meta-analyses comparing glucagon receptor agonists have included both compounds, though the predominantly Chinese clinical populations for mazdutide introduce cross-population comparison considerations (Abulehia et al., 2026).

Efficacy Comparison

Both mazdutide and survodutide have demonstrated clinically meaningful weight reduction in their respective clinical trials. In the phase 3 study of mazdutide in Chinese adults with obesity, significant weight reductions were observed across dose groups. In survodutide’s phase 2 trial, the highest dose achieved approximately 14.9% weight loss over 46 weeks. Cross-trial comparisons between survodutide vs mazdutide are complicated by differences in study populations (predominantly Chinese vs global), trial phases (phase 3 vs phase 2 for key weight data), doses evaluated, and study durations.

For glycaemic endpoints, mazdutide has demonstrated superiority over dulaglutide in HbA1c reduction in head-to-head phase 3 trials, establishing its efficacy relative to an approved GLP-1 receptor agonist (Guo et al., 2026). Survodutide’s glycaemic data from its clinical programme have similarly shown improvements in glucose parameters. The comparative assessment of glycaemic efficacy between these two dual agonists is further complicated by the different baseline diabetes severity and background therapies across their respective trial populations.

Both compounds have shown effects on hepatic fat content, consistent with the shared glucagon receptor agonism in their pharmacological profiles. Network meta-analyses comparing glucagon receptor agonists in MASLD have included both compounds, with some analyses suggesting favourable hepatic outcomes for this drug class relative to other interventions (Andonie et al., 2026).

Safety and Tolerability

Mazdutide’s safety profile from clinical trials shows predominantly gastrointestinal adverse events, including nausea, diarrhoea, and vomiting, consistent with GLP-1 receptor agonist pharmacology. The glucagon receptor component introduces monitoring considerations for hepatic function, and liver enzyme elevations have been noted in some studies. In head-to-head comparisons with dulaglutide, the gastrointestinal adverse event rates have been generally comparable. Heart rate increases have been observed, consistent with the GLP-1 receptor agonist class.

Survodutide has similarly demonstrated a predominantly gastrointestinal adverse event profile. Nausea, vomiting, and diarrhoea have been the most frequently reported events, occurring most commonly during dose escalation. A systematic review confirmed that the overall safety profile of survodutide is consistent with the dual agonist class (Xiao et al., 2025). Both compounds share the theoretical safety considerations associated with glucagon receptor agonism, including potential effects on hepatic metabolism and glucose homeostasis.

An important consideration when comparing mazdutide vs survodutide safety data is the difference in study populations. Safety profiles observed in predominantly Chinese populations may not be directly extrapolatable to global populations due to potential pharmacogenomic differences, baseline metabolic characteristics, and dietary factors. Both compounds will benefit from broader, longer-term safety data as their clinical programmes mature.

Pharmacokinetics

Mazdutide is administered as a once-weekly subcutaneous injection. The compound is a peptide-based dual agonist with structural modifications designed to achieve an appropriate half-life for weekly dosing and a balanced ratio of GLP-1 to glucagon receptor activity. Pharmacokinetic studies have characterised dose-proportional exposure and established the dosing parameters used in phase 3 trials. The compound has been studied across a range of doses, including higher doses in a dedicated phase 1 study exploring the upper dose range (Bhattachar et al., 2025).

Survodutide is also administered as a once-weekly subcutaneous injection. Like mazdutide, it is a peptide-based molecule with a pharmacokinetic profile supporting weekly administration. The phase 2 dose-ranging study evaluated multiple dose levels, with pharmacokinetic data informing the dose selection for the phase 3 SYNCHRONIZE programme.

Both mazdutide and survodutide share the practical characteristic of once-weekly subcutaneous dosing, making them directly comparable in terms of administration convenience. Neither compound is available as an oral formulation. The similar dosing schedules and routes of administration mean that pharmacokinetic differences between the two compounds are primarily driven by molecular properties rather than formulation or delivery factors.

Current Research Status

Mazdutide has completed multiple phase 3 clinical trials, primarily in Chinese populations. It has achieved regulatory milestones in China, with applications submitted or under review for both obesity and type 2 diabetes indications. The DREAMS programme continues to evaluate mazdutide in comparison with established therapies (Luo et al., 2026). Whether mazdutide will pursue regulatory approval in Western markets, and whether additional clinical trials in non-Chinese populations would be required, remains to be determined. Comparative analyses with established agents have supported mazdutide’s positioning as a viable dual agonist candidate (Ayesh et al., 2024).

Survodutide is in phase 3 development through the global SYNCHRONIZE programme. This large-scale trial programme encompasses weight management, cardiovascular outcomes, and metabolic indications (Platz et al., 2025; Rubino et al., 2026). Survodutide has not received regulatory approval in any jurisdiction. The SYNCHRONIZE programme’s global scope positions survodutide for potential regulatory submissions in multiple regions.

The competitive dynamics between survodutide vs mazdutide are shaped by geography and development strategy. Mazdutide has a head start in the Chinese market, while survodutide is pursuing a global development path. Both compounds contribute to the growing evidence base for GLP-1/glucagon dual receptor agonism as a therapeutic strategy.

Summary

Mazdutide and survodutide are both dual GLP-1 and glucagon receptor agonists administered as once-weekly subcutaneous injections. Despite targeting the same receptor pair, they are structurally distinct molecules with potentially different receptor selectivity profiles. Mazdutide has more advanced clinical data, particularly in Chinese populations, including phase 3 results and head-to-head comparisons with dulaglutide. Survodutide has phase 2 weight loss data and is in phase 3 global development through the SYNCHRONIZE programme. Key differentiators include geographic development focus, clinical programme maturity, and molecular properties. Both compounds validate the dual GLP-1/glucagon agonist approach and will contribute to understanding the optimal pharmacological strategy for metabolic disease management.

References

• Ji L et al. (2025). Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. The New England Journal of Medicine. PMID: 40421736
• le Roux CW et al. (2024). Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. The Lancet Diabetes & Endocrinology. PMID: 38330987
• Guo L et al. (2026). Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes. Nature. PMID: 41407860
• Zhu D et al. (2026). Mazdutide versus placebo in Chinese adults with type 2 diabetes. Nature. PMID: 41407859
• Luo Y et al. (2026). Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3 phase 3 trial. Contemporary Clinical Trials. PMID: 41260459
• Bhattachar SN et al. (2025). Mazdutide reduces body weight in adults with overweight or obesity: A high-dose Phase 1 trial. Diabetes, Obesity & Metabolism. PMID: 40832785
• Elmendorf AJ et al. (2026). IUPHAR review: From foe to friend: Repurposing glucagon to treat obesity and type 2 diabetes. Pharmacological Research. PMID: 41478576
• Neff GW et al. (2025). Shared mechanistic pathways of glucagon signalling: Unlocking its potential for treating obesity, MASLD and type 2 diabetes. Diabetes, Obesity & Metabolism. PMID: 41025406
• Platz E et al. (2025). Survodutide for the Treatment of Obesity: Baseline Characteristics of the SYNCHRONIZE Cardiovascular Outcomes Trial. JACC Heart Failure. PMID: 41329105
• Wharton S et al. (2026). Baseline characteristics in the SYNCHRONIZE-2 randomized phase 3 trial of survodutide. Diabetes, Obesity & Metabolism. PMID: 41216778
• le Roux CW et al. (2026). Survodutide for treatment of obesity: Baseline characteristics in SYNCHRONIZE-3. Diabetes, Obesity & Metabolism. PMID: 41187967
• Xiao YJ et al. (2025). Efficacy and safety of survodutide on glycemic control and weight loss in adults: A systematic review and meta-analysis. Diabetes, Obesity & Metabolism. PMID: 40922121
• Abulehia A et al. (2026). Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis. Endocrinology, Diabetes & Metabolism. PMID: 41787737
• Andonie CR et al. (2026). Comparative Analysis of Glucagon Receptor Agonists vs. Resmetirom in MASLD and MASH. Endocrinology, Diabetes & Metabolism. PMID: 41466530
• Ayesh H et al. (2024). Mazdutide Versus Dulaglutide for Weight Loss and Diabetes Management: Meta-Analysis of Randomized Clinical Trials. American Journal of Therapeutics. PMID: 39292847
• Rubino DM et al. (2026). Optimization of patient and site engagement in the SYNCHRONIZE phase 3 clinical trial program for survodutide. Contemporary Clinical Trials Communications. PMID: 41704810
• Deng B et al. (2024). Safety and efficacy of GLP-1 and glucagon receptor dual agonist for the treatment of type 2 diabetes and obesity: a systematic review and meta-analysis. Endocrine. PMID: 38740695